Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …

Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Background Vasopressin is commonly used as an adjunct to catecholamines to support blood
pressure in refractory septic shock, but its effect on mortality is unknown. We hypothesized …

Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19)
is limited. Objective To determine whether hydrocortisone improves outcome for …

Sepsis is the third leading cause of death worldwide and the main cause of mortality in
hospitals 1 , 2 – 3 , but the best treatment strategy remains uncertain. In particular, evidence …

Research and practice in critical care medicine have long been defined by syndromes,
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …

Objective To systematically examine the design, reporting standards, risk of bias, and claims
of studies comparing the performance of diagnostic deep learning algorithms for medical …

Background Effective targeted therapy for sepsis requires an understanding of the
heterogeneity in the individual host response to infection. We investigated this heterogeneity by …

Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs)
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …

Importance Norepinephrine is currently recommended as the first-line vasopressor in septic
shock; however, early vasopressin use has been proposed as an alternative. Objective To …